Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies

Current Alzheimer Research

Volumn 10, Issue 3, 2013, Pages 217-228

  Rosenmann, Hanna ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Efficacy; Immunotherapy; Neurofibrillary tangles; Safety; Tau; Tauopathy

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; ANTIBODY; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; PERTUSSIS TOXIN; PHF1 ANTIBODY; RECOMBINANT TAU PROTEIN; TAU PROTEIN; TAU PROTEIN[195-213]; TAU PROTEIN[207-220]; TAU PROTEIN[224-238]; TAU PROTEIN[379-408]; TAU PROTEIN[395-406]; TAU PROTEIN[420-426]; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANTIBODY PRODUCTION; CENTRAL NERVOUS SYSTEM; COGNITION; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; ENCEPHALITIS; ENCEPHALOMYELITIS; ENDOSOME; GENE MUTATION; HUMAN; IMMUNOTHERAPY; LYSOSOME; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; REVIEW; TAUOPATHY; TAUOPATHY;[207-220][195-213]; TAUOPATHY;[224-238][195-213]; TAUOPATHY;[224-238][207-220];

ALZHEIMER DISEASE; ANIMALS; HUMANS; IMMUNOTHERAPY; NEUROFIBRILLARY TANGLES; TAUOPATHIES;

EID: 84876873579     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011310030001     Document Type: Review

References (129)

1. Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer betaamyloid peptide. Proc Natl Acad Sci USA 93: 452-455 (1996).
2. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 94: 4109-4112 (1997).
3. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid betapeptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6: 916-919 (2000).
4. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 22: 721-727 (2001).
5. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982 (2000).
6. Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Desai R, et al. Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann NY Acad Sci 920: 328-331 (2000).
7. Maier M, Seabrook TJ, Lazo ND, Jiang L, Das P, Janus C, et al. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci 26: 4717-4728 (2006).
8. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985 (2000).
9. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimerdisease-like pathology in the PDAPP mouse. Nature 400: 173-177 (1999).
10. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 159: 439-447 (2001).
11. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48: 567-579 (2000).
12. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9: 448-452 (2003).
13. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9: 363-372 (2010).
14. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562 (2005).
15. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C 2003 Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46-54 (2003).
16. Wyeth Ea. plan to amend bapineuzumab phase 3 protocols. Press release [online], http://newsroomelancom/phoenixzhtml?c= 88326&p=irolnewsArticle&ID= 1272546&highlight (2009).
17. Strobel G. An eFAD prevention trial-one man's view. Alzheimer Research Forum [online] http://wwwalzforumorg/ new/detailasp?id=2273 (2009).
18. ClinicalTrials. gov Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease. http://clinicaltrialsgov/ct2/show/NCT00955409 (2012).
19. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 6: 108-119
20. Kerchner GA, Boxer AL 2010 Bapineuzumab. Expert Opin Biol Ther 10: 1121-1130 (2010).
21. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebocontrolled phase I trial. Lancet 372: 216-223 (2008).
22. Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33: 67-73 (2010).
23. Grundman M, Black R. Clinical trials of bapineuzumab, a [-amyloid-targeted immunotherapy in patients with mild to moderate Alzheimer's disease. [abstract O3-04-05] Alzheimers Dementia 4:T166 (2008).
24. Imbimbo BP, Giardina GA. gamma-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr Top Med Chem 11: 1555-1570 (2011).
25. Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW. Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta 1739:216-223 (2005).
26. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739: 198-210 (2005).
27. Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 24: 1079-1085 (2003).
28. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR, Kayed R. Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49: 10039-10041 (2010).
29. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener 6: 39 (2011).
30. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, et al. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. Faseb J 26: 1946-1959 (2012).
31. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842 (2008).
32. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 82: 239-259 (1991).
33. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42: 631-639 (1992).
34. Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, Davis KL, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol 52: 81-88 (1995).
35. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Tau suppression in a neurodegenerative mouse model improves memory function. Science 309: 476-481 (2005).
36. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 99: 6364-6369 (2002).
37. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142: 387-397 (2010).
38. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316:750-754 (2007).
39. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293:1491-1495 (2001)
40. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487-1491 (2001).
41. Oddo S, Caccamo A, Green KN, Liang K, Tran L, Chen Y, et al. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci USA 102: 3046-3051 (2005).
42. Hellstrom-Lindahl E, Court J, Keverne J, Svedberg M, Lee M, Marutle A, et al. Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. Eur J Neurosci 19: 2703-2710 (2004).
43. Hoerndli FJ, Pelech S, Papassotiropoulos A, Gotz J. Abeta treatment and P301L tau expression in an Alzheimer's disease tissue culture model act synergistically to promote aberrant cell cycle reentry. Eur J Neurosci 26: 60-72 (2007).
44. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci USA 106: 20057-20062 (2009).
45. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43: 321-332 (2004).
46. Kulic L, Kurosinski P, Chen F, Tracy J, Mohajeri MH, Li H, et al. Active immunization trial in Abeta42-injected P301L tau transgenic mice. Neurobiol Dis 22: 50-56 (2006).
47. Wilcock DM, Gharkholonarehe N, Van Nostrand WE, Davis J, Vitek MP, Colton CA. Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J Neurosci 29: 7957-7965 (2009).
48. Ma QL, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, Ubeda OJ, et al. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res 83: 374-384 (2006).
49. Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, La-Ferla FM. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 281: 39413-39423 (2006).
50. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14: 11-20 (2004).
51. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64:129-131 (2005).
52. Boche D, Donald J, Love S, Harris S, Neal JW, Holmes C, et al. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Acta Neuropathol 120: 13-20 (2010).
53. Serrano-Pozo A, William CM, Ferrer I, Uro-Coste E, Delisle MB, Maurage CA, et al. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain 133: 1312-1327 (2010).
54. Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 63: 1459-1467 (2006).
55. Furlan R, Brambilla E, Sanvito F, Roccatagliata L, Olivieri S, Bergami A, et al. Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain 126: 285-291 (2003).
56. Monsonego A, Imitola J, Petrovic S, Zota V, Nemirovsky A, Baron R, et al. Abeta-induced meningoencephalitis is IFNgamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 103: 5048-5053 (2006).
57. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM et al. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27: 9115-9129 (2007).
58. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25: 402-405 (2000).
59. Mercken M, Vandermeeren M, Lubke U, Six J, Boons J, Van de Voorde A, et al. Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol 84: 265-272 (1992).
60. Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognizes tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett 189: 167-169 (1995).
61. Zheng-Fischhofer Q, Biernat J, Mandelkow EM, Illenberger S, Godemann R, Mandelkow E et al. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur J Biochem 252: 542-552 (1998).
62. Rosenmann H, Grigoriadis N, Eldar-Levy H, Avital A, Rozenstein L, Touloumi O, et al. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp Neurol 212: 71-84 (2008).
63. Boimel M, Grigoriadis N, Lourbopoulos A, Rozenstein L, Touloumi O, Mizrachi R, et al. Inflammation in the CNS increases Alzheimer's disease related neurofibrillary tangle burden: A study of experimental autoimmune encephalomyelitis in a transgenic animal model for neurofibrillary tangles. Neurology 66: 279 (2006).
64. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 224: 472-485 (2010).
65. Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30:16559-16566 (2010).
66. Bi M, Ittner A, Ke YD, Gotz J, Ittner LM. Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice. PLoS One 6: e26860 (2011).
67. Gotz J, Chen F, Barmettler R, Nitsch RM. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276: 529-534 (2001).
68. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez F, Grosjean M, Zommer N et al. Targeting phospho-Ser422 by active tau immunotherapy in the THY-22Tau mouse model: a suitable therapeitic approach. Curr Alzheimer Res 9: 397-405 (2012).
69. Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, et al. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169: 599-616 (2006).
70. Novac M. Tau vaccine: active immunization with a misfolded tau protein attenuates tau pathology in a transgenic rat model of tauopathy. Alzheimers dement 5: P93 (2009).
71. Theunis C, Crespo Biel N, Borghgraef P, Devijver H, Gafner V et al. Protein Tau: target for immunotherapy: pre-clinical evaluationin transgenic mice. Neurodegener Dis 8: Suppl 1 (2011).
72. Higuchi N. Molecular mediators of amiloidosis-inflammation coupling in Alzheimer' disease: in vivo evidence in humans and animal models. Neurodegener Dis 8: Suppl 1 (2011).
73. Krishnamurthy P, Gonzalez V, Rajamohamedsait HB, Sigurdsson EM. Immunization with a pseudophosphorylated tau epitope clears tau pathology in a mouse model. Alzheimer's & Dementia 7: S481-S482 (2011).
74. Taniguchi T, Sumida M, Hiraoka S, Tomoo K, Kakehi T, Minoura K et al. Effects of different anti-tau antibodies on tau fibrillogenesis: RTA-1 and RTA-2 counteract tau aggregation. FEBS Lett 579: 1399-1404 (2005).
75. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118: 658-667 (2011).
76. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 286: 34457-34467 (2011).
77. Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 22: 9340-9351 (2002).
78. Castillo-Carranza D, Lasagna-Reeves C, Estes D, Barrett A, Dineley K, Jackson G et al. Modulation of tau oligomers by passive vaccination. Soc Neurosci Abstr 347:11 (2010).
79. Friedman R. AD Vaccine Targeting Tau Promising in Early Animal Studies. Neurology Today 11: 20 (2011).
80. Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. Curr Alzheimer Res 8: 659-665 (2011).
81. Morgan D, Lee D, Brownlow M, Selenica M, Reid P, Alvarez J et al. Opposing roles of microglial activation in amyloid depositing and tau depositing transgenic mice. Neurodegener Dis 1: Suppl 1 (2011).
82. Rosenmann H, Meiner Z, Geylis V, Abramsky O, Steinitz M. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci Lett 410: 90-93 (2006).
83. Banks WA. Are the extracellular [correction of extracelluar] pathways a conduit for the delivery of therapeutics to the brain? Curr Pharm Des 10: 1365-1370 (2004).
84. Fabian RH, Petroff G. Intraneuronal IgG in the central nervous system: uptake by retrograde axonal transport. Neurology 37: 1780-1784 (1987).
85. Kozlowski GP, Sterzl I, Nilaver G. Localization patterns for immunoglobulins and albumins in the brain suggest diverse mechanisms for their transport across the blood-brain barrier (BBB). Prog Brain Res 91: 149-154 (1992).
86. Nerenberg ST, Prasad R. Radioimmunoassays for Ig classes G, A, M, D, and E in spinal fluids: normal values of different age groups. J Lab Clin Med 86: 887-898 (1975).
87. Zlokovic BV, Skundric DS, Segal MB, Lipovac MN, Mackic JB, Davson H. A saturable mechanism for transport of immunoglobulin G across the blood-brain barrier of the guinea pig. Exp Neurol 107: 263-270 (1990).
88. Boettger MK, Weishaupt A, Geis C, Toyka KV, Sommer C. Mild experimental autoimmune encephalitis as a tool to induce bloodbrain barrier dysfunction. J Neural Transm 117: 165-169 (2010).
89. Alafuzoff I, Adolfsson R, Grundke-Iqbal I, Winblad B. Bloodbrain barrier in Alzheimer dementia and in non-demented elderly. An immunocytochemical study. Acta Neuropathol 73: 160-166 (1987).
90. Gu J, Sigurdsson EM. Immunotherapy for tauopathies. J Mol Neurosci 45: 690-695 (2011).
91. Friden PM, Walus LR, Watson P, Doctrow SR, Kozarich JW, Backman C, et al. Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science 259: 373-377 (1993).
92. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE. Passage of amyloid beta protein antibody across the bloodbrain barrier in a mouse model of Alzheimer's disease. Peptides 23: 2223-2226 (2002).
93. Sigurdsson EM. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res 6: 446-450 (2009).
94. Fabian RH. Uptake of antineuronal IgM by CNS neurons: comparison with antineuronal IgG. Neurology 40: 419-422 (1990).
95. Greenlee JE, Burns JB, Rose JW, Jaeckle KA, Clawson S. Uptake of systemically administered human anticerebellar antibody by rat Purkinje cells following blood-brain barrier disruption. Acta Neuropathol 89: 341-345 (1995).
96. Meeker ML, Meeker RB, Hayward JN. Accumulation of circulating endogenous and exogenous immunoglobulins by hypothalamic magnocellular neurons. Brain Res 423: 45-55 (1987).
97. Mohamed HA, Mosier DR, Zou LL, Siklos L, Alexianu ME, Engelhardt JI, et al. Immunoglobulin Fc gamma receptor promotes immunoglobulin uptake, immunoglobulin-mediated calcium increase, and neurotransmitter release in motor neurons. J Neurosci Res 69: 110-116 (2002).
98. Upender MB, Dunn JA, Wilson SM, Naegele JR. Immunoglobulin molecules are present in early-generated neuronal populations in the rat cerebral cortex and retina. J Comp Neurol 384: 271-282 (1997).
99. Dalmau J, Furneaux HM, Rosenblum MK, Graus F, Posner JB. Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/ sensory neuronopathy. Neurology 41: 1757-1764 (1991).
100. Okun E, Mattson MP, Arumugam TV. Involvement of Fc receptors in disorders of the central nervous system. Neuromolecular Med 12: 164-178 (2010).
101. Herz J, Kowal RC, Ho YK, Brown MS, Goldstein JL. Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver. J Biol Chem 265: 21355-21362 (1990).
102. Sigurdsson EM. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis 15: 157-168 (2008).
103. Brandt R, Leger J, Lee G. Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J Cell Biol 131: 1327-1340 (1995).
104. Ekinci FJ, Shea TB. Phosphorylation of tau alters its association with the plasma membrane. Cell Mol Neurobiol 20:497-508 (2000).
105. Gauthier-Kemper A, Weissmann C, Golovyashkina N, Sebo-Lemke Z, Drewes G, Gerke V, et al. The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner. J Cell Biol 192: 647-661 (2011).
106. Mori H, Kondo J, Ihara Y. Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science 235:1641-1644 (1987).
107. Garcia-Sierra F, Jarero-Basulto JJ, Kristofikova Z, Majer E, Binder LI, Ripova D. Ubiquitin is Associated with Early Truncation of Tau Protein at Aspartic Acid(421) during the Maturation of Neurofibrillary Tangles in Alzheimer's Disease. Brain Pathol 22: 240-50 (2012).
108. Lim F, Hernandez F, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol Cell Neurosci 18:702-714 (2001).
109. Lin WL, Lewis J, Yen SH, Hutton M, Dickson DW. Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau. J Neurocytol 32: 1091-1105 (2003).
110. Krishnamurthy PK, Deng Y, Sigurdsson EM. Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model. Front Psychiatry 2: 59 (2011).
111. Tampellini D, Magrane J, Takahashi RH, Li F, Lin MT, Almeida CG et al. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J Biol Chem 282: 18895-18906 (2007).
112. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46: 857-868 (2005).
113. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 6: e19338 (2011).
114. Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ. Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357: 500-503 (1992).
115. Yamazaki T, Koo EH, Selkoe DJ. Trafficking of cell-surface amyloid beta-protein precursor. II. Endocytosis, recycling and lysosomal targeting detected by immunolocalization. J Cell Sci 109 (Pt 5): 999-1008 (1996).
116. Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 15: 433-442 (2006).
117. Wong ES, Tan JM, Soong WE, Hussein K, Nukina N, Dawson VL, et al. Autophagy-mediated clearance of aggresomes is not a universal phenomenon. Hum Mol Genet 17: 2570-2582 (2008).
118. Wang Y, Martinez-Vicente M, Kruger U, Kaushik S, Wong E, Mandelkow EM, et al. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet 18:4153-4170 (2009).
119. Zhang JY, Peng C, Shi H, Wang S, Wang Q, Wang JZ. Inhibition of autophagy causes tau proteolysis by activating calpain in rat brain. J Alzheimers Dis 16: 39-47 (2009).
120. Kenessey A, Nacharaju P, Ko LW, Yen SH. Degradation of tau by lysosomal enzyme cathepsin D: implication for Alzheimer neurofibrillary degeneration. J Neurochem 69: 2026-2038 (1997).
121. Nakanishi H. Neuronal and microglial cathepsins in aging and agerelated diseases. Ageing Res Rev 2: 367-381 (2003).
122. Gomez-Ramos A, Diaz-Hernandez M, Cuadros R, Hernandez F, Avila J. Extracellular tau is toxic to neuronal cells. FEBS Lett 580:4842-4850 (2006).
123. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284: 12845-12852 (2009).
124. Kim W, Lee S, Jung C, Ahmed A, Lee G, Hall GF. Interneuronal transfer of human tau between Lamprey central neurons in situ. J Alzheimers Dis 19: 647-664 (2010).
125. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11: 909-913 (2009).
126. Gotz J, Ittner A, Ittner LM. Tau-targeted treatment strategies in Alzheimer's disease. Br J Pharmacol 165: 1246-59 (2011).
127. Ishizawa K, Dickson DW. Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol 60: 647-657 (2001).
128. Boimel M, Grigoriadis N, Lourbopoulos A, Touloumi O, Rosenmann D, Abramsky O, et al. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J Neuropathol Exp Neurol 68: 314-325 (2009).
129. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53: 337-351 (2007).